fda compounded semaglutide enforcement news Drug compounders sue FDA over declaration ending Wegovy shortage

The push to make weight-loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and

20.51

★★★★☆4.8 (126)

In 2023, the FDA deemed 19 peptide drugs too unsafe to be dispensed by compounding pharmacies, which mix components of approved drugs to create bespoke medication for people who have trouble taking

28.71

★★★★★4.9 (98)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

24.25

★★★★★5.0 (157)

Compounded' weight-loss drugs are a growing problem for state regulators • NC Newsline

28.80

★★★★★4.7 (84)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

22.13

★★★★★4.9 (203)

The FDA is cracking down on ‘misleading’ compounded GLP-1s from telehealth companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety,

25.03

★★★★★5.0 (176)

Feds warn telehealth companies about "illegal marketing" of compounded GLP-1s

22.68

★★★★★4.8 (132)